image
Healthcare - Biotechnology - NASDAQ - GB
$ 10.42
-1.08 %
$ 7.44 B
Market Cap
-10.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one ROIV stock under the worst case scenario is HIDDEN Compared to the current market price of 10.4 USD, Roivant Sciences Ltd. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one ROIV stock under the base case scenario is HIDDEN Compared to the current market price of 10.4 USD, Roivant Sciences Ltd. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one ROIV stock under the best case scenario is HIDDEN Compared to the current market price of 10.4 USD, Roivant Sciences Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ROIV

image
$13.0$13.0$12.5$12.5$12.0$12.0$11.5$11.5$11.0$11.0$10.5$10.5$10.0$10.0$9.5$9.5$9.0$9.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
125 M REVENUE
103.65%
4.24 B OPERATING INCOME
460.92%
4.23 B NET INCOME
479.32%
-765 M OPERATING CASH FLOW
9.26%
5.2 B INVESTING CASH FLOW
11854.55%
419 M FINANCING CASH FLOW
-16.04%
9.02 M REVENUE
101.52%
-274 M OPERATING INCOME
19.70%
25.3 M NET INCOME
113.50%
-207 M OPERATING CASH FLOW
22.32%
454 M INVESTING CASH FLOW
113.79%
-273 M FINANCING CASH FLOW
-150.24%
Balance Sheet Roivant Sciences Ltd.
image
Current Assets 6.73 B
Cash & Short-Term Investments 6.54 B
Receivables 82.8 M
Other Current Assets 108 M
Non-Current Assets 491 M
Long-Term Investments 248 M
PP&E 66 M
Other Non-Current Assets 177 M
90.57 %3.43 %Total Assets$7.2b
Current Liabilities 267 M
Accounts Payable 53.2 M
Short-Term Debt 21.9 M
Other Current Liabilities 192 M
Non-Current Liabilities 507 M
Long-Term Debt 478 M
Other Non-Current Liabilities 29.3 M
6.88 %2.83 %24.76 %61.74 %3.79 %Total Liabilities$774.0m
EFFICIENCY
Earnings Waterfall Roivant Sciences Ltd.
image
Revenue 125 M
Cost Of Revenue 28 M
Gross Profit 96.8 M
Operating Expenses -4.13 B
Operating Income 4.24 B
Other Expenses 10.8 M
Net Income 4.23 B
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m00125m(28m)97m4b4b(11m)4bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
77.59% GROSS MARGIN
77.59%
3399.19% OPERATING MARGIN
3399.19%
3484.86% NET MARGIN
3484.86%
72.86% ROE
72.86%
60.21% ROA
60.21%
60.48% ROIC
60.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Roivant Sciences Ltd.
image
00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)(800m)(800m)(900m)(900m)Jul '20Jul '2020212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024
Net Income 4.23 B
Depreciation & Amortization 22 M
Capital Expenditures -1.38 M
Stock-Based Compensation 200 M
Change in Working Capital 19 M
Others -5.24 B
Free Cash Flow -767 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Roivant Sciences Ltd.
image
Wall Street analysts predict an average 1-year price target for ROIV of $16.6 , with forecasts ranging from a low of $12.5 to a high of $20 .
ROIV Lowest Price Target Wall Street Target
12.5 USD 19.96%
ROIV Average Price Target Wall Street Target
16.6 USD 59.55%
ROIV Highest Price Target Wall Street Target
20 USD 91.94%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Roivant Sciences Ltd.
image
Sold
0-3 MONTHS
16.2 M USD 2
3-6 MONTHS
23 M USD 2
6-9 MONTHS
96.1 M USD 6
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE. globenewswire.com - 1 week ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D. globenewswire.com - 1 week ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3. investors.com - 1 month ago
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP. globenewswire.com - 1 month ago
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. globenewswire.com - 1 month ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. globenewswire.com - 1 month ago
All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to Buy Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 months ago
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Brian Cheng - JPMorgan Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C. seekingalpha.com - 2 months ago
Roivant Sciences Tops Q3 Expectations Biopharmaceutical company Roivant Sciences (ROIV 0.18%) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million surpassed estimates of $5 million, reflecting the company's strategic momentum. fool.com - 2 months ago
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.24. zacks.com - 2 months ago
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab topline results from pivotal trial in myasthenia gravis (MG) and initial results from period 1 of trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Progress in ongoing LNP litigation, with the summary judgment phase in the Moderna case taking place across the second and third quarters of calendar year 2025 and a jury trial scheduled for September 2025 Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $5.2 billion at December 31, 2024, not including a one-time regulatory milestone of $75 million received in January for the approval of VTAMA in atopic dermatitis and $113 million of external capital raised in Immunovant's January private placement “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in cutaneous sarcoidosis. globenewswire.com - 2 months ago
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade) Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. seekingalpha.com - 2 months ago
8. Profile Summary

Roivant Sciences Ltd. ROIV

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 7.44 B
Dividend Yield 0.00%
Description Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Contact 11-12 St. James's Square, London, SW1Y 4LB https://roivant.com
IPO Date Dec. 8, 2020
Employees 908
Officers Mr. Richard Pulik Chief Financial Officer Mr. Josh Chen J.D. General Counsel Dr. Mayukh Sukhatme M.D. President, Chief Investment Officer & Director Dr. Eric Venker M.D., Pharm.D. President & Chief Operating Officer Mr. Alex Gasner Executive Vice President of Roivant Health Dr. Matt Maisak Chief Operating Officer of Roivant Platforms Dr. Srini Ramanathan Ph.D. Chief Development Officer Mr. Drew Kramer Chief Information Officer Ms. Kelly Graff Head of People Mr. Matthew Gline Chief Executive Officer & Director